Medindia LOGIN REGISTER
Medindia

New Test to Determine Cognitive Capacities of Patients With Schizophrenia

by Shirley Johanna on Sep 16 2017 4:32 PM

New Test to Determine Cognitive Capacities of Patients With Schizophrenia
A new test has been designed to determine the cognitive capacities of patients of schizophrenia. The test was developed by a research team from the Universitat Autònoma de Barcelona (UAB), in collaboration with the University of Oviedo and the Biomedical Research Networking Center in Mental Health (CIBERSAM).
The test consists of a battery of assessments chosen by the research team which permits them, in 20 minutes or less depending on the case, to examine patients’ short-term memory capacities, mental agility and also organizational capacities.

The research, which forms part of the doctoral thesis of Sílvia Zaragoza Domingo, is the result of a pioneering study lasting 6 months in which 257 professionals worked with a sample of 700 individuals representative of the population diagnosed with schizophrenia in Spain. The study, which goes by the name of EPICOG-SCH, identified a battery of four assessments in order to conduct the test.

One of the main novelties of the battery of assessments chosen by researchers and led by Silvia Zaragoza lies in the fact that, in addition to being short, they consist of tests available to doctors and psychologists experts in mental health. Moreover, the tests are available in several languages, which makes it easier to use them with patients of different origins.

Another advantage is that they are easy to administer, and therefore facilitates being used by health professionals in order to assess patients with schizophrenia. The test permits health professionals to assess, study and comment on symptoms of the disorder which normally are not taken into account and which could serve to treat each case in the best possible manner.

"In schizophrenia, it is desirable for the patient to be as independent and function as best possible, although that does not always happen," explains Sílvia Zaragoza. She goes on to say that "this test allows each patient to better adapt to his life. For example, if a patient is slower mentally, but short-term memory is not affected, he or she will have more chances of leading an independent life than someone whose memory is also affected."

This battery of assessments represents a very important step towards offering patients specific examinations, which can be conducted through their regular mental health centers or private centers. After an initial examination, the clinics can also conduct a follow-up of patients and also confirm whether changes in medications worsen attention span or memory, a common complaint among patients at their routine visits.

Advertisement
The study was published in the journal Schizophrenia Research: Cognition, printed by the Schizophrenia International Research Society (SIRS), one of the most prestigious journals on schizophrenia worldwide, and is part of the doctoral thesis of researcher Sílvia Zaragoza under the UAB’s PhD program in Psychiatry. Zaragoza, expert in clinical research, led the study which also included the collaboration of researchers Julio Bobes and María Paz García-Portilla, both professors of psychiatry at the University of Oviedo and members of CIBERSAM.

The test will be developed and commercialized by Psyncro (Neuropsychological Research Organization sl), a company founded by Sílvia Zaragoza. Her doctoral supervisor and advisor were CIBERSAM researchers from the UAB Department of Psychiatry Antoni Bulbena and Víctor Pérez, while professors from the University of Girona Joan Vilalta and Manuel de Gracia directed her academic work.

Advertisement
Source-Eurekalert


Advertisement